Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today

Core Insights - BioMarin Pharmaceutical's stock rose nearly 5% following the release of its quarterly results, contrasting with a 0.4% decline in the S&P 500 index on the same day [1] Financial Performance - The company's revenue for Q4 2024 reached $747 million, representing a 16% increase year-over-year [2] - Non-GAAP adjusted net income nearly doubled to $180 million ($0.92 per share), compared to $95 million in the previous year [2] - Both revenue and adjusted net income significantly exceeded analyst estimates of $711 million and $0.55 per share, respectively [3] Future Guidance - For the entirety of 2025, BioMarin projects total revenue between $3.1 billion and $3.2 billion, with adjusted net income expected to be between $4.20 and $4.40 per share [4] - Consensus analyst estimates for 2025 are $3.1 billion in revenue and $4.16 per share in adjusted net income [4] Company Strengths - BioMarin has developed a strong product lineup and demonstrates effective marketing and sales capabilities [5] - The company is positioned for a prosperous 2025, indicating a positive outlook for its future [5]